Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advexin gets rolling?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Introgen is requesting clearance for a rolling BLA submission for Advexin, the firm announces Dec. 23. Submission would begin immediately and complete before the end of 2005. Introgen is seeking accelerated approval for the orphan head and neck cancer therapy, which also has fast track status. Two Phase III studies are underway. Introgen recently released Phase II data in a sub-population of recurrent, unresectable head and neck cancer showing tumor growth control in 41% of patients, with an objective response rate of 15%. Median survival was 13.5 months for patiens with tumor growth control and 31.4 months for patients with objective responses...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel